What development phase is Ibunac in?

Ibunac is FDA-approved (marketed).

What is the generic name of Ibunac?

IBUFENAC is the generic (nonproprietary) name of Ibunac.

Last reviewed 2026-04-20 · How we verify

Ibunac (IBUFENAC)

FDA-approved withdrawn Small molecule Quality 10/100

IBUFENAC (Ibunac) is a marketed nonsteroidal anti-inflammatory drug (NSAID) with a key composition patent expiring in 2028. Its primary competitive advantage lies in its strong patent protection, which provides a barrier to generic entry until 2028. The primary risk is the presence of multiple established competitors, including celecoxib, diclofenac, flurbiprofen, ibuprofen, and indomethacin, with some already off-patent and available as generics.

At a glance

Generic name	IBUFENAC
Drug class	ibufenac
Target	Prostaglandin G/H synthase 2
Modality	Small molecule
Therapeutic area	Immunology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ibunac CI brief — competitive landscape report
Ibunac updates RSS · CI watch RSS